Thus, this study aimed to investigate the expression of MIS/AMH type II receptors in patient-derived endometrial cancer cells to identify the mechanism of growth inhibition in MIS/AMH-treated endometrial cancer cells and to determine whether MIS/AMH administration could be an effective targeted therapy for MIS/AMH receptor-expressing tumors. The gene discussed is AMHR2; the disease is endometrial cancer.